由买买提看人间百态

topics

全部话题 - 话题: hematide
(共0页)
h****r
发帖数: 2056
1
10 Biotech Stocks On the Line
By Adam Feuerstein
http://www.thestreet.com/_yahoo/story/10700109/1/10-biotech-stocks-on-the-line.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA
十檔受到重大研究影響的生技股 ZT
InterMune (ITMN: 報價, 研究資料) 股價上漲五暴漲180%,擁有該檔股票的投資人,
上週的投資價值就翻漲一倍。 由於美國食品藥物管理局核准藥物,對生技股的影響非
常大,往往導致個股大漲大跌,因生技股投資人必須非常留意這些個股事件的波動。
以下十檔個股未來幾個月就有新藥正在等待核准。通過的業者就可望像InterMune大漲
,如果失敗,就很可能大跌。
1. Affymax (AFFY: 報價, 研究資料) :研發慢性腎疾病導致之貧血藥物Hematide。預
估期間:第二季。 Hematide是每月一次的注射藥物,用來治療慢性腎病導致至貧血。
這款藥物的開發包括四次大型的階段三研究,將對Amgen的貧血藥物... 阅读全帖
f**********g
发帖数: 2252
2
来自主题: _pennystock版 - AFFX
大胖, could u do some study about its product tonight or u have done?
Affymax, Inc. is a biopharmaceutical company developing drugs to improve the
treatment of serious and often life-threatening conditions. Its product
candidate, Hematide (peginesatide), is designed to treat anemia associated
with chronic renal failure. Hematide is a synthetic peptide-based
erythropoiesis stimulating agent (ESA) designed to stimulate production of
red blood cells. The Company completed treatment and follow up of p... 阅读全帖
b*****h
发帖数: 783
3
来自主题: _pennystock版 - 可以建仓ALXA了
他们应该NDA Hematide to treat patients in dialysis.
(共0页)